PDGFRA non-D842V exon 18 mutations in GIST are imatinib-SENSITIVE (distinct from D842V)....
Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.
| ID | BMA-PDGFRA-EXON18-NON-D842-GIST |
|---|---|
| Tipo | Relevância terapêutica |
| Estado | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Doenças | DIS-GIST |
| Fontes | SRC-CIVIC SRC-IRIS-OBRIEN-2003 SRC-NCCN-MELANOMA-2025 |
Fatos de ação
| Biomarcador | BIO-PDGFRA |
|---|---|
| Variante | exon 18 non-D842V mutation (e.g., D846Y, N848K, Y849K, deletion DIM842-844) |
| Doença | DIS-GIST |
| Nível ESCAT | IB |
| Combinações recomendadas | imatinib 400 mg/day (1L advanced/metastatic non-D842V exon 18 PDGFRA), avapritinib (alternative; investigational) |
| Resumo das provas | PDGFRA non-D842V exon 18 mutations in GIST are imatinib-SENSITIVE (distinct from D842V). Imatinib 400 mg/day is standard 1L — responses comparable to KIT exon 11 GIST. Avapritinib also active. Genotyping is mandatory to distinguish D842V (avapritinib) from non-D842V exon 18 (imatinib-first). |
Notas
ESCAT IB. OncoKB Level 1. Source-gap as DIS-GIST. Adjuvant imatinib applies in high-risk resected non-D842V PDGFRA GIST (3 yr).
Usado por
Não há referências reversas encontradas no corpus YAML.